Peptide Compounding Vote Raises New Questions for Drug Developers

A federal advisory committee has taken the first formal step toward allowing pharmacies to compound four popular but unapproved peptides.¹ This decision could reshape how these products move through the US supply chain and set precedent for how the FDA treats a growing category of self-assembled protein-based compounds.

Meeting this week, the outside advisers voted in a narrow majority to recommend adding BPC-157, KPV, and TB-500 to the list of substances state-licensed compounding pharmacies may prepare for patients with a prescription.^1,2 Eight members voted in favor, 6 voted against, and 1 abstained. A fourth peptide, MOTs-C, which is being evaluated for obesity and osteoporosis, passed by a 7-5 vote with two abstentions. The panel is scheduled to reconvene to consider 3 additional peptides.

The recommendations arrive as regulators and industry weigh competing pressures: expanding legal access to products already circulating widely outside any clinical oversight, versus maintaining evidence standards for medicines that have not completed human trials.¹

What Makes These Compounds Different from Approved Peptide Drugs?

Peptides are built from the same molecular building blocks the body uses to construct proteins, and several, including insulin and diabetes and weight-loss injectables, have cleared the full approval process.¹ The substances under review this week have not. Instead, many are sold online under research-use exemptions, reaching consumers for purposes such as muscle recovery and longevity without a doctor's supervision or standardized dosing information. Analysts have estimated the broader market for these products could reach $2 billion to $3 billion if pharmacy compounding is formally sanctioned.

The regulatory question predates this week's meeting.¹ In 2023, federal officials found that nearly 20 peptides raised safety concerns and blocked their compounding. That position began to shift this year when the reclassification of a dozen peptides moved several toward eligibility for the pathway now under discussion.

Why Should Manufacturing and Development Professionals Be Watching?

For companies operating within the traditional development pipeline, this proceeding is less about individual products than about the durability of evidence-based review.¹ Agency staff reviewers recommended against expanding compounding access, citing scant safety and effectiveness data, and officials used the hearing to note that compounded products carry no required labeling on dosing or risk, urging sponsors to pursue formal applications and controlled human trials instead. A decision that allows unapproved peptides onto pharmacy shelves without that data effectively creates a parallel track to the one manufacturers have long been required to follow, with implications for quality standards, liability exposure, and competitive dynamics between compounders and approved-drug sponsors.

The committee's makeup added to that tension.¹ Seven of the 14 members were added ahead of the meeting from clinics or businesses that sell peptide treatments, and most of those who voted in favor have industry ties. “All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members,” said Emily Hilliard, a Department of Health and Human Services spokesperson.¹ However, not every panelist was convinced the process reflected sound science.

“I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science,” said Elizabeth Rebello, panel member and professor, University of Texas.¹

The agency is not bound by its advisers' recommendations and has yet to issue a final determination.¹ Whatever it decides will help clarify where the line sits between legitimate expansion of patient access and a bypass of the clinical evidence framework that governs the rest of the peptide drug category.

References

1. Reuters. US FDA advisers weigh restrictions on seven peptides as industry presses expansion. July 23, 2026. https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/
2. Reuters. FDA panel votes to place popular peptide BPC-157 on compounding list. July 23, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/